Genentech's goal is to deliver innovative medicines to patients with serious or life-threatening medical conditions. Since its founding in 1976, the company has focused its drug discovery efforts on therapies that would fill unmet needs. Today, Genentech manufactures and commercializes multiple biotherapeutics for critical medical conditions in the areas of oncology, immunology, and disorders of tissue growth and repair — giving Genentech one of the leading product portfolios in the biotech industry.

Adverse events with any of Genentech's products can be reported to Genentech at (888) 835-2555.

BioOncology Avastin® (bevacizumab)
Anti-VEGF antibody
For use in combination with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum; in combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC)

Herceptin® (Trastuzumab)
Anti-HER2 antibody
For metastatic breast cancer in HER2-overexpressed tumors in combination with paclitaxel and as a single agent for patients who have received one or more chemotherapy regimens for metastatic disease; as part of a treatment regimen containing doxorubicin, cyclophosphamide and paclitaxel, for the adjuvant treatment of patients with HER2-overexpressing breast cancer; and as a single agent for the adjuvant treatment of HER2-overexpressing node-negative (ER/PR negative or with one high-risk feature) or node-positive breast cancer, following multi-modality anthracycline-based therapy

Rituxan® (Rituximab)
Anti-CD20 antibody
For relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens; for previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy; and for the treatment of non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent, after first-line CVP chemotherapy

Tarceva® (erlotinib)
Small molecule HER1/EGFR inhibitor
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen; in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy

For more information about Genentech BioOncology, please visit www.biooncology.com.

Immunology Raptiva® (efalizumab)
Anti-CD11a antibody
For chronic moderate-to-severe plaque psoriasis in adults age 18 or older

Rituxan® (Rituximab)
Anti-CD20 antibody
For use in combination with methotrexate (MTX) for reducing signs and symptoms and to slow the progression of structural damage in adult patients with moderately- to severely-active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies

Xolair® (Omalizumab) for Subcutaneous Use
Anti-IgE antibody
For moderate-to-severe persistent asthma in adults and adolescents

Tissue Growth and Repair Activase® (Alteplase)
A tissue-plasminogen activator
For acute myocardial infarction, acute ischemic stroke and acute massive pulmonary embolism

Cathflo® Activase® (Alteplase)
Thrombolytic agent
For the restoration of function to central venous access devices as assessed by the ability to withdraw blood

Lucentis® (ranibizumab injection)
Antibody fragment
For the treatment of neovascular (wet) age-related macular degeneration (AMD)

Nutropin® [somatropin (rDNA origin) for injection]
Growth hormone
For GHD in children and adults; growth failure associated with chronic renal insufficiency prior to kidney transplantation; short stature associated with Turner syndrome; long-term treatment of children with idiopathic (of unknown origin) short stature

Nutropin AQ® [somatropin (rDNA origin) injection]
Liquid formulation growth hormone
For GHD in children and adults; growth failure associated with chronic renal insufficiency prior to kidney transplantation; short stature associated with Turner syndrome; long-term treatment of children with idiopathic (of unknown origin) short stature

Nutropin AQ Pen® for use with Nutropin AQ Pen® Cartridge [somatropin (rDNA origin) injection]
Liquid formulation growth hormone in a prefilled cartridge delivery device

Pulmozyme® (dornase alfa)
Inhalation Solution
For management of cystic fibrosis (including patients under age 5)

TNKase® (Tenecteplase)
Single-bolus thrombolytic agent
For the treatment of acute myocardial infarction